The Mythbusting Episode | Essential: The Pharmacy Compounding Podcast

In this edition of Essential, we’ve got updates on some big compounding news — like the FDA’s long-overdue decision to remove the boxed warning from some menopause hormone-replacement therapy drugs. (And yes, that’s important for compounding pharmacists!)
We also look at the hubbub at FDA over what (allegedly) was behind the decision that would have effectively banned compounding with desiccated thyroid extract, plus some stories from the states, and more.
This month’s deep dive: Mythbusting, compounded-GLP-1 style! What have the big drugmakers been saying, and how much of it is true? They’re spreading stories, but our experts put them to the test. Don’t miss out!

Links
Join APC today: https://a4pc.org/membership 
FDA to remove boxed warning from HRT medications: https://archive.ph/R8DJD 
An example of what appears to be an op-ed pushed by a pharma company. The writer, a “former healthcare professional,”doesn’t appear to exist: https://archive.ph/OPNWr 
Find a legitimate, licensed compounding pharmacy: https://a4pc.org/isitlegit 
Benefits of becoming an APC PFM: https://a4pc.org/pfm